SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
SOCRA CCRP Exam Newest 2025
200 Questions and Correct Detailed Answers with Rationales
Society of Clinical Research Associates — Certified Clinical Research Professional
Aligned with 2025 SOCRA CCRP Examination Content Outline • ICH E6(R2) GCP
Note: Beginning January 1, 2026, exam content reflects ICH E6(R3)
Regulatory: 21 CFR Parts 11, 50, 54, 56, 312, 812 • 45 CFR Part 46
Cognitive Mix: 25% Recall • 55% Application • 20% Analysis | Format: 75% Scenario, 20% Recall, 5% Calculation
This 200-question SOCRA Certified Clinical Research Professional (CCRP) examination is fully aligned with the
2025 SOCRA CCRP examination content outline and Good Clinical Practice (GCP) standards under ICH E6(R2)
(with the transition to ICH E6(R3) effective January 1, 2026). The exam covers three integrated content domains:
Research Study Start-Up (40%), Research Study Implementation (50%), and Research Study Closure (10%). Each
question includes a detailed rationale grounded in CFR citations (21 CFR Parts 11, 50, 54, 56, 312, 812; 45 CFR Part
46), ICH E6(R2) GCP sections, and the foundational ethical principles of the Nuremberg Code, Belmont Report,
and Declaration of Helsinki. The exam emphasizes scenario-based reasoning, regulatory compliance,
investigator/sponsor/IRB responsibility differentiation, informed consent content requirements, adverse event
reporting pathways, investigational product accountability, financial disclosure timing, record retention
durations, and study closeout/final reporting requirements for advanced clinical research professionals
preparing for SOCRA CCRP certification.
Section 1: Research Study Start-Up (Q1-Q80) — 40%
Q1: A sponsor is developing a Phase II trial for a new oncology drug. The principal investigator asks the
clinical research coordinator which regulatory pathway applies to the study. The drug has not been
previously approved by the FDA. Which of the following is the correct regulatory pathway for this
study?
A. An Investigational Device Exemption (IDE) is required because the drug is being tested in humans
B. An Investigational New Drug (IND) application is required because the drug is being studied in
humans and is not yet FDA-approved [CORRECT]
C. No regulatory submission is needed because Phase II trials only require IRB approval
D. A Biologics License Application (BLA) is required for all new oncology drugs
Correct Answer: B
Rationale: An IND application is required under 21 CFR 312 for any clinical investigation of a drug in humans when
the drug is not yet FDA-approved or is being studied for a new indication. An IDE (choice A) applies to medical
devices, not drugs. While IRB approval is required (choice C), it does not replace the IND requirement. A BLA (choice
D) is submitted after clinical trials to request marketing authorization, not before trials begin. The IND allows the
sponsor to ship the investigational drug across state lines and administer it to human subjects.
Page 1 | SOCRA CCRP Exam — 200 Questions
,SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
Q2: A clinical research coordinator is preparing an informed consent form for a study involving adults
with limited reading ability. Which of the following approaches best ensures the consent language is
understandable to subjects per 21 CFR 50.25 and ICH E6(R2) 4.8?
A. Use the medical terminology from the protocol so that subjects receive complete scientific information
B. Replace the term 'myalgia' with 'muscle aches' and use plain language at approximately an 8th-grade
reading level [CORRECT]
C. Have subjects read the Investigator's Brochure before signing consent
D. Provide a glossary of medical terms at the end of the consent form so subjects can look up unfamiliar
words
Correct Answer: B
Rationale: Per 21 CFR 50.25 and ICH E6(R2) 4.8.6, informed consent language must be understandable to the subject
or their legally authorized representative, avoiding technical jargon. Replacing 'myalgia' with 'muscle aches' reflects
the regulatory requirement for lay language, generally targeting an 8th-grade reading level. Using medical
terminology (choice A) violates the regulation. The Investigator's Brochure (choice C) is a technical document for
investigators, not subjects. A glossary (choice D) does not substitute for clear, plain language in the body of the
consent form.
Q3: A 14-year-old is being enrolled in a clinical trial. The clinical research coordinator is preparing the
consent documentation. Which of the following best describes the appropriate consent process for this
minor?
A. Only the 14-year-old's assent is required; parental permission is not needed because the study is minimal
risk
B. Both parental permission AND the child's assent must be obtained and documented, unless the IRB
waives assent [CORRECT]
C. Only parental permission is required; assent is optional for adolescents
D. The minor can sign the adult consent form without any additional parental involvement
Correct Answer: B
Rationale: Under 21 CFR 50 Subpart D and 45 CFR 46 Subpart D, research involving children requires both parental
permission and the child's assent (when the child is capable of providing assent, generally ages 7-17), unless the IRB
waives assent under specific criteria. Choice A is incorrect because parental permission is required for children
unless waived. Choice C is incorrect because assent is required when the child is capable. Choice D is incorrect
because minors cannot legally consent; parental permission plus child assent is required. The IRB determines
whether assent is appropriate based on the child's age, maturity, and psychological state.
Q4: An investigator is completing FDA Form 1572 for a drug study. By signing this form, the investigator
is certifying which of the following statements?
A. That the investigator has read and understood the Investigator's Brochure and will conduct the study
in compliance with the protocol and applicable regulations [CORRECT]
B. That the investigator will financially compensate all subjects for any adverse events
C. That the sponsor has reviewed and approved the investigator's qualifications
D. That the IRB has approved the study before any subjects are enrolled
Correct Answer: A
Rationale: FDA Form 1572 (Statement of Investigator, 21 CFR 312.53) is the investigator's commitment to conduct the
study in compliance with regulations and the protocol. By signing, the investigator certifies they have read and
understood the Investigator's Brochure, will conduct the study per the protocol, will personally conduct or supervise
the investigation, will inform subjects that the drug is investigational, and will comply with IRB review and
recordkeeping requirements. Choice B (financial compensation) is not part of the 1572 certification. Choice C is the
sponsor's responsibility, not the investigator's certification. Choice D is a regulatory requirement but the 1572 itself
does not certify IRB approval timing.
Page 2 | SOCRA CCRP Exam — 200 Questions
,SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
Q5: According to the Belmont Report, which ethical principle is primarily served by requiring
equitable selection of study subjects so that no single group bears disproportionate research risk?
A. Respect for Persons
B. Beneficence
C. Justice [CORRECT]
D. Autonomy
Correct Answer: C
Rationale: The Belmont Report identifies three ethical principles: Respect for Persons (informed consent, protecting
autonomy), Beneficence (maximizing benefits, minimizing harms, risk/benefit assessment), and Justice (fair
distribution of research burdens and benefits, equitable subject selection). The principle of Justice specifically
requires that no group (e.g., the poor, minorities, the critically ill) be systematically burdened with research risks
while another group reaps the benefits. Respect for Persons (choice A) addresses autonomy and consent.
Beneficence (choice B) addresses risk/benefit analysis. Autonomy (choice D) is encompassed by Respect for Persons
but is not one of the three named Belmont principles.
Q6: A sponsor is preparing a clinical trial for a new cardiovascular device that presents a significant
risk to subjects. Which regulatory submission is required before the device can be studied in humans?
A. An IND application to the FDA Center for Drug Evaluation and Research
B. An IDE application to the FDA Center for Devices and Radiological Health [CORRECT]
C. A 510(k) premarket notification
D. Only IRB approval is required for significant risk device studies
Correct Answer: B
Rationale: An Investigational Device Exemption (IDE) is required under 21 CFR 812 for clinical investigations of
medical devices. For significant risk devices, both FDA approval of the IDE AND IRB approval are required before the
study can begin. An IND (choice A) applies to drugs, not devices. A 510(k) (choice C) is for marketing clearance of a
device that is substantially equivalent to a legally marketed predicate, not for conducting clinical investigations.
Choice D is incorrect because significant risk device studies require both FDA IDE approval and IRB approval, not
IRB approval alone.
Q7: A clinical research coordinator is preparing to submit a study to the IRB. Which of the following
documents is NOT typically required as part of the initial IRB submission package?
A. The protocol and any amendments
B. The informed consent form
C. The investigator's personal tax returns from the previous year [CORRECT]
D. The Investigator's Brochure or package insert
Correct Answer: C
Rationale: Initial IRB submissions typically include the protocol (and amendments), informed consent form,
Investigator's Brochure or package insert, recruitment materials, FDA Form 1572 (for drug studies), financial
disclosure forms (FDA 3454), and CVs of investigators. Personal tax returns (choice C) are not relevant to subject
safety, study design, or investigator qualifications and are not part of an IRB submission. Choices A, B, and D are all
standard IRB submission documents required under 21 CFR 56.109.
Page 3 | SOCRA CCRP Exam — 200 Questions
, SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
Q8: Under 21 CFR 54 (Financial Disclosure by Clinical Investigators), how long must a clinical
investigator agree to update their financial information after the completion of the study?
A. 6 months
B. 1 year [CORRECT]
C. 2 years
D. 5 years
Correct Answer: B
Rationale: Per 21 CFR 54.4, clinical investigators must agree to update their financial information for 1 year after
completion of the study. This allows the FDA to assess potential conflicts of interest that could affect the reliability of
the study data. The FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators)
and Form 3455 (Disclosure) are used to document this information. Choices A, C, and D are incorrect timeframes.
The 1-year update period ensures the FDA has complete financial disclosure information when reviewing marketing
applications that may rely on the study data.
Q9: A Phase III trial is being designed to evaluate the efficacy and safety of a new drug compared to the
current standard of care. Which of the following best describes the primary purpose of a Phase III
trial?
A. To determine the safe dosage range and pharmacokinetics in healthy volunteers
B. To evaluate the drug's mechanism of action and pharmacological effects
C. To gather additional evidence of effectiveness and safety in a larger population to support regulatory
approval [CORRECT]
D. To monitor long-term adverse effects after the drug has been marketed
Correct Answer: C
Rationale: Phase III trials are large, randomized, controlled (often multi-center) studies designed to confirm
effectiveness, monitor side effects, compare the drug to commonly used treatments, and collect information that will
allow the drug to be used safely — supporting regulatory approval (NDA/BLA). Phase I (choice A) determines safe
dosage and pharmacokinetics in healthy volunteers. Phase II (choice B) evaluates efficacy in a small group with the
target disease and may study mechanism of action. Phase IV (choice D) is post-marketing surveillance to monitor
long-term effects after approval. Phase III is the pivotal stage that typically provides the primary evidence for
marketing approval.
Q10: A sponsor wants to use an expedited review pathway for a study involving a minor change to a
previously approved study. Which of the following statements about expedited review under 21 CFR
56.110 is correct?
A. Expedited review can be used for initial review of any minimal risk study [CORRECT]
B. Expedited review can be used to approve a study that involves more than minimal risk
C. The IRB chair or experienced reviewer can approve major changes to the protocol
D. Expedited review eliminates the requirement for continuing review
Correct Answer: A
Rationale: Per 21 CFR 56.110, expedited review may be used by the IRB chair or an experienced voting member for:
(1) certain categories of minimal-risk research for initial review, and (2) minor changes in previously approved
research during the approval period. Choice B is incorrect because expedited review only applies to minimal-risk
research. Choice C is incorrect because only MINOR changes (not major changes) can be approved via expedited
review; major changes require full board review. Choice D is incorrect — while some minimal-risk studies may not
require continuing review, expedited review itself does not automatically eliminate continuing review requirements.
The list of categories eligible for expedited review is published by the FDA and OHRP.
Page 4 | SOCRA CCRP Exam — 200 Questions
SOCRA CCRP Exam Newest 2025
200 Questions and Correct Detailed Answers with Rationales
Society of Clinical Research Associates — Certified Clinical Research Professional
Aligned with 2025 SOCRA CCRP Examination Content Outline • ICH E6(R2) GCP
Note: Beginning January 1, 2026, exam content reflects ICH E6(R3)
Regulatory: 21 CFR Parts 11, 50, 54, 56, 312, 812 • 45 CFR Part 46
Cognitive Mix: 25% Recall • 55% Application • 20% Analysis | Format: 75% Scenario, 20% Recall, 5% Calculation
This 200-question SOCRA Certified Clinical Research Professional (CCRP) examination is fully aligned with the
2025 SOCRA CCRP examination content outline and Good Clinical Practice (GCP) standards under ICH E6(R2)
(with the transition to ICH E6(R3) effective January 1, 2026). The exam covers three integrated content domains:
Research Study Start-Up (40%), Research Study Implementation (50%), and Research Study Closure (10%). Each
question includes a detailed rationale grounded in CFR citations (21 CFR Parts 11, 50, 54, 56, 312, 812; 45 CFR Part
46), ICH E6(R2) GCP sections, and the foundational ethical principles of the Nuremberg Code, Belmont Report,
and Declaration of Helsinki. The exam emphasizes scenario-based reasoning, regulatory compliance,
investigator/sponsor/IRB responsibility differentiation, informed consent content requirements, adverse event
reporting pathways, investigational product accountability, financial disclosure timing, record retention
durations, and study closeout/final reporting requirements for advanced clinical research professionals
preparing for SOCRA CCRP certification.
Section 1: Research Study Start-Up (Q1-Q80) — 40%
Q1: A sponsor is developing a Phase II trial for a new oncology drug. The principal investigator asks the
clinical research coordinator which regulatory pathway applies to the study. The drug has not been
previously approved by the FDA. Which of the following is the correct regulatory pathway for this
study?
A. An Investigational Device Exemption (IDE) is required because the drug is being tested in humans
B. An Investigational New Drug (IND) application is required because the drug is being studied in
humans and is not yet FDA-approved [CORRECT]
C. No regulatory submission is needed because Phase II trials only require IRB approval
D. A Biologics License Application (BLA) is required for all new oncology drugs
Correct Answer: B
Rationale: An IND application is required under 21 CFR 312 for any clinical investigation of a drug in humans when
the drug is not yet FDA-approved or is being studied for a new indication. An IDE (choice A) applies to medical
devices, not drugs. While IRB approval is required (choice C), it does not replace the IND requirement. A BLA (choice
D) is submitted after clinical trials to request marketing authorization, not before trials begin. The IND allows the
sponsor to ship the investigational drug across state lines and administer it to human subjects.
Page 1 | SOCRA CCRP Exam — 200 Questions
,SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
Q2: A clinical research coordinator is preparing an informed consent form for a study involving adults
with limited reading ability. Which of the following approaches best ensures the consent language is
understandable to subjects per 21 CFR 50.25 and ICH E6(R2) 4.8?
A. Use the medical terminology from the protocol so that subjects receive complete scientific information
B. Replace the term 'myalgia' with 'muscle aches' and use plain language at approximately an 8th-grade
reading level [CORRECT]
C. Have subjects read the Investigator's Brochure before signing consent
D. Provide a glossary of medical terms at the end of the consent form so subjects can look up unfamiliar
words
Correct Answer: B
Rationale: Per 21 CFR 50.25 and ICH E6(R2) 4.8.6, informed consent language must be understandable to the subject
or their legally authorized representative, avoiding technical jargon. Replacing 'myalgia' with 'muscle aches' reflects
the regulatory requirement for lay language, generally targeting an 8th-grade reading level. Using medical
terminology (choice A) violates the regulation. The Investigator's Brochure (choice C) is a technical document for
investigators, not subjects. A glossary (choice D) does not substitute for clear, plain language in the body of the
consent form.
Q3: A 14-year-old is being enrolled in a clinical trial. The clinical research coordinator is preparing the
consent documentation. Which of the following best describes the appropriate consent process for this
minor?
A. Only the 14-year-old's assent is required; parental permission is not needed because the study is minimal
risk
B. Both parental permission AND the child's assent must be obtained and documented, unless the IRB
waives assent [CORRECT]
C. Only parental permission is required; assent is optional for adolescents
D. The minor can sign the adult consent form without any additional parental involvement
Correct Answer: B
Rationale: Under 21 CFR 50 Subpart D and 45 CFR 46 Subpart D, research involving children requires both parental
permission and the child's assent (when the child is capable of providing assent, generally ages 7-17), unless the IRB
waives assent under specific criteria. Choice A is incorrect because parental permission is required for children
unless waived. Choice C is incorrect because assent is required when the child is capable. Choice D is incorrect
because minors cannot legally consent; parental permission plus child assent is required. The IRB determines
whether assent is appropriate based on the child's age, maturity, and psychological state.
Q4: An investigator is completing FDA Form 1572 for a drug study. By signing this form, the investigator
is certifying which of the following statements?
A. That the investigator has read and understood the Investigator's Brochure and will conduct the study
in compliance with the protocol and applicable regulations [CORRECT]
B. That the investigator will financially compensate all subjects for any adverse events
C. That the sponsor has reviewed and approved the investigator's qualifications
D. That the IRB has approved the study before any subjects are enrolled
Correct Answer: A
Rationale: FDA Form 1572 (Statement of Investigator, 21 CFR 312.53) is the investigator's commitment to conduct the
study in compliance with regulations and the protocol. By signing, the investigator certifies they have read and
understood the Investigator's Brochure, will conduct the study per the protocol, will personally conduct or supervise
the investigation, will inform subjects that the drug is investigational, and will comply with IRB review and
recordkeeping requirements. Choice B (financial compensation) is not part of the 1572 certification. Choice C is the
sponsor's responsibility, not the investigator's certification. Choice D is a regulatory requirement but the 1572 itself
does not certify IRB approval timing.
Page 2 | SOCRA CCRP Exam — 200 Questions
,SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
Q5: According to the Belmont Report, which ethical principle is primarily served by requiring
equitable selection of study subjects so that no single group bears disproportionate research risk?
A. Respect for Persons
B. Beneficence
C. Justice [CORRECT]
D. Autonomy
Correct Answer: C
Rationale: The Belmont Report identifies three ethical principles: Respect for Persons (informed consent, protecting
autonomy), Beneficence (maximizing benefits, minimizing harms, risk/benefit assessment), and Justice (fair
distribution of research burdens and benefits, equitable subject selection). The principle of Justice specifically
requires that no group (e.g., the poor, minorities, the critically ill) be systematically burdened with research risks
while another group reaps the benefits. Respect for Persons (choice A) addresses autonomy and consent.
Beneficence (choice B) addresses risk/benefit analysis. Autonomy (choice D) is encompassed by Respect for Persons
but is not one of the three named Belmont principles.
Q6: A sponsor is preparing a clinical trial for a new cardiovascular device that presents a significant
risk to subjects. Which regulatory submission is required before the device can be studied in humans?
A. An IND application to the FDA Center for Drug Evaluation and Research
B. An IDE application to the FDA Center for Devices and Radiological Health [CORRECT]
C. A 510(k) premarket notification
D. Only IRB approval is required for significant risk device studies
Correct Answer: B
Rationale: An Investigational Device Exemption (IDE) is required under 21 CFR 812 for clinical investigations of
medical devices. For significant risk devices, both FDA approval of the IDE AND IRB approval are required before the
study can begin. An IND (choice A) applies to drugs, not devices. A 510(k) (choice C) is for marketing clearance of a
device that is substantially equivalent to a legally marketed predicate, not for conducting clinical investigations.
Choice D is incorrect because significant risk device studies require both FDA IDE approval and IRB approval, not
IRB approval alone.
Q7: A clinical research coordinator is preparing to submit a study to the IRB. Which of the following
documents is NOT typically required as part of the initial IRB submission package?
A. The protocol and any amendments
B. The informed consent form
C. The investigator's personal tax returns from the previous year [CORRECT]
D. The Investigator's Brochure or package insert
Correct Answer: C
Rationale: Initial IRB submissions typically include the protocol (and amendments), informed consent form,
Investigator's Brochure or package insert, recruitment materials, FDA Form 1572 (for drug studies), financial
disclosure forms (FDA 3454), and CVs of investigators. Personal tax returns (choice C) are not relevant to subject
safety, study design, or investigator qualifications and are not part of an IRB submission. Choices A, B, and D are all
standard IRB submission documents required under 21 CFR 56.109.
Page 3 | SOCRA CCRP Exam — 200 Questions
, SOCRA CCRP Exam 2025 | 200 Questions & Detailed Answers ICH E6(R2)/E6(R3) GCP • 21 CFR • 45 CFR 46
Q8: Under 21 CFR 54 (Financial Disclosure by Clinical Investigators), how long must a clinical
investigator agree to update their financial information after the completion of the study?
A. 6 months
B. 1 year [CORRECT]
C. 2 years
D. 5 years
Correct Answer: B
Rationale: Per 21 CFR 54.4, clinical investigators must agree to update their financial information for 1 year after
completion of the study. This allows the FDA to assess potential conflicts of interest that could affect the reliability of
the study data. The FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators)
and Form 3455 (Disclosure) are used to document this information. Choices A, C, and D are incorrect timeframes.
The 1-year update period ensures the FDA has complete financial disclosure information when reviewing marketing
applications that may rely on the study data.
Q9: A Phase III trial is being designed to evaluate the efficacy and safety of a new drug compared to the
current standard of care. Which of the following best describes the primary purpose of a Phase III
trial?
A. To determine the safe dosage range and pharmacokinetics in healthy volunteers
B. To evaluate the drug's mechanism of action and pharmacological effects
C. To gather additional evidence of effectiveness and safety in a larger population to support regulatory
approval [CORRECT]
D. To monitor long-term adverse effects after the drug has been marketed
Correct Answer: C
Rationale: Phase III trials are large, randomized, controlled (often multi-center) studies designed to confirm
effectiveness, monitor side effects, compare the drug to commonly used treatments, and collect information that will
allow the drug to be used safely — supporting regulatory approval (NDA/BLA). Phase I (choice A) determines safe
dosage and pharmacokinetics in healthy volunteers. Phase II (choice B) evaluates efficacy in a small group with the
target disease and may study mechanism of action. Phase IV (choice D) is post-marketing surveillance to monitor
long-term effects after approval. Phase III is the pivotal stage that typically provides the primary evidence for
marketing approval.
Q10: A sponsor wants to use an expedited review pathway for a study involving a minor change to a
previously approved study. Which of the following statements about expedited review under 21 CFR
56.110 is correct?
A. Expedited review can be used for initial review of any minimal risk study [CORRECT]
B. Expedited review can be used to approve a study that involves more than minimal risk
C. The IRB chair or experienced reviewer can approve major changes to the protocol
D. Expedited review eliminates the requirement for continuing review
Correct Answer: A
Rationale: Per 21 CFR 56.110, expedited review may be used by the IRB chair or an experienced voting member for:
(1) certain categories of minimal-risk research for initial review, and (2) minor changes in previously approved
research during the approval period. Choice B is incorrect because expedited review only applies to minimal-risk
research. Choice C is incorrect because only MINOR changes (not major changes) can be approved via expedited
review; major changes require full board review. Choice D is incorrect — while some minimal-risk studies may not
require continuing review, expedited review itself does not automatically eliminate continuing review requirements.
The list of categories eligible for expedited review is published by the FDA and OHRP.
Page 4 | SOCRA CCRP Exam — 200 Questions
